Expanded Access Program for Revumenib
NCT05918913 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-09-05
Summary
This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.
Conditions
- Relapsed/Refractory Acute Leukemia
Interventions
- DRUG
-
Revumenib administered orally every 12 hours.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Syndax Pharmaceuticals
Eligibility
- Min Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
NCT06575296 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958 ·Status: RECRUITING ·Phase: PHASE3
-
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
NCT07250646 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
NCT00360672 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
NCT00251368 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT06177067 ·Status: RECRUITING ·Phase: PHASE1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074 ·Status: RECRUITING ·Phase: PHASE2
-
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
NCT03534323 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
NCT07283640 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
NCT05886049 ·Status: RECRUITING ·Phase: PHASE1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
NCT05776134 ·Status: AVAILABLE
-
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT05360160 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784 ·Status: COMPLETED ·Phase: PHASE3
-
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
NCT00691938 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
NCT01116193 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BN104 in the Treatment of Acute Leukemia
NCT06052813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
NCT00352365 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
NCT05732103 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
NCT00449761 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02537613 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study Of The Selective PKC-β Inhibitor MS- 553
NCT03492125 ·Status: TERMINATED ·Phase: PHASE1/PHASE2